RITODRINE HCL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RITODRINE HCL (RITODRINE HCL).
Selective beta-2 adrenergic receptor agonist; stimulates beta-2 receptors in uterine smooth muscle, causing relaxation and inhibiting uterine contractions. Also has some beta-1 activity at higher doses.
| Metabolism | Primarily hepatic via conjugation with glucuronic acid and sulfate; minor metabolism via oxidative pathways. CYP450 enzymes not majorly involved. |
| Excretion | Renal: 70-90% as unchanged drug and metabolites. Biliary/fecal: 10-30%. |
| Half-life | Terminal elimination half-life: 15-17 hours in pregnant women; 2-4 hours in non-pregnant adults. Context: Half-life prolonged in pregnancy due to increased Vd and decreased clearance. |
| Protein binding | 90-95% bound to albumin. |
| Volume of Distribution | Vd: 0.8-1.3 L/kg in pregnancy. Indicates extensive tissue distribution, crossing placenta readily. |
| Bioavailability | Oral: 30-40% due to first-pass metabolism; IV: 100%; IM: 100%. |
| Onset of Action | IV: 1-5 minutes; IM: 5-10 minutes; Oral: 30-60 minutes. Onset correlates with tocolytic effect. |
| Duration of Action | IV: 2-4 hours; IM: 2-3 hours; Oral: 3-6 hours. Duration depends on dose and route; titrated to maternal heart rate. |
10 mg orally every 2 hours for preterm labor; initially 50-100 mcg/min IV, titrated to response, maximum 350 mcg/min.
| Dosage form | Injectable |
| Renal impairment | No specific adjustment; use with caution in severe renal impairment (GFR < 30 mL/min) due to risk of accumulation. |
| Liver impairment | No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment. |
| Pediatric use | Not recommended for pediatric use; safety and efficacy not established. |
| Geriatric use | Use with caution; reduced dosing may be necessary due to decreased hepatic and renal function; monitor for cardiovascular effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RITODRINE HCL (RITODRINE HCL).
| Breastfeeding | Ritodrine is excreted into breast milk in small amounts; the milk-to-plasma ratio (M/P) has not been well established, but estimated M/P is approximately 0.3-1.2. No adverse effects in nursing infants have been reported. However, due to potential for beta-agonist effects (e.g., tachycardia), caution is advised. The American Academy of Pediatrics considers ritodrine compatible with breastfeeding. |
| Teratogenic Risk | Ritodrine is a beta-2 adrenergic agonist used as a tocolytic. In animal studies, ritodrine has been associated with fetal abnormalities (e.g., skeletal and cardiovascular defects) at high doses. Human data are limited; however, use in pregnancy is generally restricted to the second and third trimesters for acute tocolysis. First-trimester exposure: insufficient data, but theoretical risk based on animal studies. Second and third trimesters: fetal tachycardia, hypoglycemia, and hypocalcemia have been reported with maternal use. Risk of maternal pulmonary edema and myocardial ischemia may also affect fetal oxygenation. |
■ FDA Black Box Warning
None.
| Serious Effects |
Maternal tachyarrhythmias, severe hypertension, pulmonary hypertension, uncontrolled diabetes mellitus, hyperthyroidism, chorioamnionitis, intrauterine fetal death, preeclampsia/eclampsia, cord compression, and antepartum hemorrhage requiring immediate delivery.
| Precautions | Maternal pulmonary edema (especially with concurrent corticosteroid use), maternal tachycardia and hypotension, myocardial ischemia, hypokalemia, hyperglycemia, fetal/neonatal effects (tachycardia, hypoglycemia, hypocalcemia). Monitor maternal heart rate, blood pressure, blood glucose, and potassium. |
Loading safety data…
| Fetal Monitoring | Maternal: Frequent monitoring of heart rate, blood pressure, serum glucose, electrolytes (especially potassium), and ECG for arrhythmias. Monitor for signs of pulmonary edema (dyspnea, rales) and myocardial ischemia. Fetal: Continuous fetal heart rate monitoring for tachycardia, and assessment for hypoglycemia and hypocalcemia after delivery. Initial stabilization requires hospitalization. |
| Fertility Effects | No specific studies on human fertility. Animal studies have not reported adverse effects on fertility. Ritodrine may cause transient hyperglycemia and hypokalemia, which could theoretically affect ovulation, but no direct evidence of impaired fertility. |